Behavioral perspectives on the neuroscience of drug addiction.

J Exp Anal Behav

Department of Pharmacology, University of Michigan, Ann Arbor 48109-0632, USA.

Published: November 2005

Neuroscientific approaches to drug addiction traditionally have been based on the premise that addiction is a process that results from brain changes that in turn result from chronic administration of drugs of abuse. An alternative approach views drug addiction as a behavioral disorder in which drugs function as preeminent reinforcers. Although there is a fundamental discrepancy between these two approaches, the emerging neuroscience of reinforcement and choice behavior eventually may shed light on the brain mechanisms involved in excessive drug use. Behavioral scientists could assist in this understanding by devoting more attention to the assessment of differences in the reinforcing strength of drugs and by attempting to develop and validate behavioral models of addiction.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1389786PMC
http://dx.doi.org/10.1901/jeab.2005.101-04DOI Listing

Publication Analysis

Top Keywords

drug addiction
12
addiction
5
behavioral
4
behavioral perspectives
4
perspectives neuroscience
4
drug
4
neuroscience drug
4
addiction neuroscientific
4
neuroscientific approaches
4
approaches drug
4

Similar Publications

Background & Aims: Hepatic encephalopathy (HE), one of the most serious prognostic factors for mortality in alcohol-related cirrhosis (ALD cirrhosis), is not recorded in Danish healthcare registries. However, treatment of HE with lactulose, the universal first-line treatment, can be identified through data on filled prescriptions. This study aimed to investigate if lactulose can be used as a surrogate marker of HE.

View Article and Find Full Text PDF

Online interest in ADHD predicts ADHD medication prescriptions in Australia from 2004 to 2023: A time-series analysis revealing COVID-19-related acceleration.

Australas Psychiatry

January 2025

College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia; Consortium of Australian-Academic Psychiatrists for Independent Policy Research and Analysis, Canberra, ACT, Australia; Department of Psychiatry, Monash University, Clayton, VIC, Australia.

Objective: Attention-deficit hyperactivity disorder (ADHD) medication prescriptions in Australia have grown sharply in recent years. We examined the association between online interest in ADHD and prescriptions.

Methods: Monthly Pharmaceutical Benefits Scheme (PBS) and Repatriation PBS (RPBS) Item Reports of ADHD prescriptions and Australian ADHD-related Google Trends (GT) data (2004-2023) were sourced.

View Article and Find Full Text PDF

Analgesic Overdose in Patients With Dental Pain. A Cross-Sectional Study in Two Dental Emergency Clinics.

Basic Clin Pharmacol Toxicol

February 2025

Department of Odontology, Section of Oral Biology and Immunopathology, University of Copenhagen, Copenhagen, Denmark.

Dental pain is common, and many patients use analgesics to alleviate the pain. Analgesics are readily accessible, and overdosing may lead to severe complications. This study explores the extent of analgesic overdosing in patients with dental pain.

View Article and Find Full Text PDF

Background: Women involved in the criminal legal system have elevated rates of opioid use disorder, which is treatable, and HIV, which is preventable with pre-exposure prophylaxis (PrEP). There are significant social and structural barriers to integrated delivery of PrEP and medications for opioid use disorder (MOUD), limiting women's ability to access these life-saving interventions. In a two parallel-arm randomized controlled trial, we are assessing an innovative eHealth delivery model that integrates PrEP with MOUD and is tailored to meet the specific needs of women involved in the criminal legal system.

View Article and Find Full Text PDF

Background: In the United States, complete abstinence persists as the standard for demonstrating recovery success from substance use disorders (SUDs), apart from alcohol use disorder (AUD). Although the FDA has recently indicated openness for non-abstinence outcomes as treatment targets, the traditional benchmark of complete abstinence for new medications to treat SUDs remains a hurdle and overshadows other non-abstinent outcomes desired by people with SUDs (e.g.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!